Bin Tie Bio Completes Over RMB 100 Million Series A Financing Led by SDIC Chuangye

Investment Circle (ID: pedaily2012) October 31 news, ImmuXell Biotech LtD. (referred to as "ImmuXell Biotech") announcedExceeding 100 Million YuanARound of financing, this round led by SDIC Venture Capital Co., Ltd., with participation from Guangzhou Huangpu Biomedical Industry Investment Fund Management Co., Ltd., Yuanxi Haihe (Tianjin) Biomedical Industry Fund Partnership (Limited Partnership), and others.Support ImmuXell Biotech in promoting the research and development of new technologies, the implementation of commercial production, and the strategic layout of international operations. The funds raised in this round will be used to accelerate the advancement of the registration clinical trial application for a novel TCR-T cell therapy product targeting the KRAS G12V mutation, as well as the product development and international cooperation for multiple subsequent innovative pipelines.

ImmuXell Biotech was established in January 2021, with a registered capital of 20 million yuan. Located in the Kangqiao Industrial Zone of Shanghai's Zhangjiang Science City, it is a clinical-stage biopharmaceutical technology innovation enterprise focused on the research and development and production of breakthrough immunotherapy drugs. Its main product is a novel immune cell preparation targeting solid tumors.

Dr. Hu Hongming, the founder of ImmuXell Biotech, has dedicated many years to the field of tumor immunology. With extensive experience in basic and clinical research on cancer immunology as well as translational medicine, several immunotherapy drugs he originally developed have entered clinical trials. Building on this foundation, ImmuXell Biotech has developed multiple product pipelines with independent intellectual property rights. Among them, the TCR-T cell therapy product targeting KRAS mutations has completed TCR screening, in vitro functional validation, and in vivo efficacy testing. Investigator-initiated trials (IIT) for advanced pancreatic ductal adenocarcinoma have been carried out across multiple clinical centers, and the product is now in the preparation stage for IND submission. Additionally, significant progress has been made in ImmuXell Biotech’s other product pipelines, including TCR-NK products that can be used as allogeneic cell therapies, and TCR fusion protein products that can be mass-produced and supplied off-the-shelf.

Since its establishment, ImmuXell Biotech has achieved rapid development in platform construction, pipeline setup, and product layout. The future goal is to identify shared gene mutations and tumor neoantigens, and to develop a series of TCR products for treating recurrent and refractory malignant tumors such as pancreatic cancer. The company aims to combine personalization with universality in cell therapy products, enhancing the efficacy and accessibility of cell therapies to benefit a broader patient population.

Regarding this investment, SDIC Venture Capital Co., Ltd., Guangzhou Huangpu Biomedical Industry Investment Fund Management Co., Ltd., and Yuanxi Haihe (Tianjin) Biomedical Industry Fund Partnership (Limited Partnership) all expressedThey have high expectations for ImmuXell Biotech's innovative capabilities and development potential in the field of immune cell therapy, hoping that this round of funding will advance the research and development process of ImmuXell Biotech’s TCR-T innovative drug for treating relapsed and refractory solid tumors. This investment marks another significant layout by SDIC Venture Capital Co., Ltd., Guangzhou Huangpu Biomedical Industry Investment Fund Management Co., Ltd., and Yuanxi Haihe (Tianjin) Biomedical Industry Fund Partnership (Limited Partnership) in the life sciences and healthcare sector. Moving forward, they will continue to actively seek out and support life science and healthcare projects with innovation and market potential, jointly promoting the rapid development of China's life sciences and healthcare industry.